Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Smith & Nephew plc (SNN) vs Workday Inc (WDAY) Price & Performance

Smith & Nephew plcTrade
Workday IncTrade

Price performance (Past 24H)

Key statistics

Smith & Nephew plc vs Workday Inc — how do they compare? Smith & Nephew plc trades at $30.16 (market cap $12.64B), while Workday Inc trades at $139.5 (market cap $36.36B). The key difference: Workday Inc is far larger — about 2.9× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.57% dividend while Workday Inc pays none. Which is the better fit depends on your goals.

SNNWDAY
Market Cap
$12.64B$36.36B
Sector
HealthTechnology
52-Week High
$38.70$247.69
52-Week Low
$28.73$112.55
Enterprise Value
$15.41B$35.81B
Dividend Yield
2.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Smith & Nephew plc

Smith & Nephew (SNN) trades at $30.43, down 0.54% on the day, with mixed technical signals showing a neutral overall stance. The company demonstrates improving fundamentals with 2024 revenue of $5.81 billion and net income of $412 million, representing a 7.09% margin. Recent product launches including the LYNX COBLATION Wand and CORI XT robotics platform highlight ongoing innovation. Cash flow trends show strong operational performance with $987 million from operations in 2024.

SNN presents a balanced investment case with improving profitability and product innovation offset by recent earnings misses. The stock trades at reasonable valuations (P/E 21.36, P/S 2.17) with analyst consensus leaning Hold (68%). Key risks include execution challenges and competitive pressures, while catalysts include robotics expansion and wound care leadership. The $500 million buyback program supports shareholder returns.

Workday Inc

Workday (WDAY) trades at $146.92, up 1.48% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $151.36. The company has beaten EPS estimates for three consecutive quarters, with Q2 2026 expected at $2.62. Revenue grew to $8.45 billion in 2025, though net income margin compressed to 6.22% from 19.02% in 2024. Positive sentiment is driven by AI product expansion, but a lawsuit over AI bias and net cash outflows present headwinds.

WDAY offers growth potential with strong subscription revenue and AI-driven deal expansion, yet high P/E of 45.1 suggests premium valuation. Risks include competitive pressures, regulatory scrutiny, and reliance on enterprise spending. Analyst consensus is bullish with 55.55% buy ratings, but investors should monitor execution on profitability and legal challenges.

Returns comparison

Trailing returns across standard periods

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN

About Workday Inc

Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.

Read more on WDAY